Early vs. late G-CSF for preventing infections in lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares giving a medication called G-CSF (which helps your body make white blood cells to fight infection) early versus later after chemotherapy. The goal is to see which timing works best to prevent infections for people with non-Hodgkin's lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with non-Hodgkin's lymphoma
- You are scheduled to receive standard chemotherapy
- You can understand and speak Thai well
- You are able to attend follow-up visits after chemotherapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a drug called G-CSF affects certain immune cells (MDSCs) and cancer stem cells in people with a specific type of advanced lung cancer (adenocarcinoma). It may help doctors understand how to make current treatments work better.
This trial tests whether patients can safely skip a preventive white-blood-cell growth shot (G-CSF) while receiving a common breast cancer chemotherapy regimen. It may help reduce injections and side effects, while watching closely for fevers and low white blood counts.
This trial tests whether adding a medicine called G-CSF (which helps your body make more white blood cells) to standard antibiotics works better than antibiotics alone for children with fever and low white blood cells caused by cancer treatment.
This trial tests a new way to give a medicine that helps your body make white blood cells after chemotherapy for breast cancer. It may help prevent serious infections.
This trial tests if a study drug (Thiopegfilgrastim) can help prevent a dangerous drop in white blood cells (bone marrow suppression) in people with esophageal or lung cancer who are getting chemo and radiation. It may reduce your risk of infection during treatment.
This trial tests a medication called efbemalenograstim alfa to help prevent a serious drop in white blood cells (febrile neutropenia) in people with advanced lung cancer who are starting their first round of chemo. It may reduce the risk of infection and other complications.
Hear when a new Granulocyte Colony Stimulating Factor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.